Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020

Repatha Original List Price Option Will be Discontinued Effective Dec. 31, 2019Almost Half of All Medicare Patients Will Have an Affordable, Low Fixed Copay in 2020THOUSAND OAKS, Calif., Oct. 24, 2019 -- (Healthcare Sales & Marketing Network)-- A...Biopharmaceuticals, Cardiology, Reimbursement
Amgen, Repatha, evolocumab